The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) includes two primary levels of risk assessment, evaluating extended genetic risk factors followed by clinical characteristics as well as family history of breast cancer for BRCA1/2 mutation carriers [60]. This evidence concerns the gene BRCA1 and breast cancer.